{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Immunotherapeutic Agent" in comments (approximate match)
Status:
Investigational
Source:
NCT04266301: Phase 3 Interventional Completed Myelodysplastic Syndromes
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02605525: Phase 2 Interventional Withdrawn Immunoglobulin A Nephropathy
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03215030: Phase 1/Phase 2 Interventional Completed Multiple Myeloma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03512314: Phase 3 Interventional Completed XIAP Deficiency
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001789: Phase 2 Interventional Completed Glomerulonephritis, Membranoproliferative
(1999)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00037700: Phase 2 Interventional Completed Rheumatoid Arthritis
(2001)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02225366: Phase 1/Phase 2 Interventional Completed Melanoma
(2015)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02350673: Phase 1 Interventional Completed Solid Tumors
(2015)
Source URL:
Class:
PROTEIN
